TNFRSF10C

TNFRSF10C (DcR1/TRAIL-R3) is a GPI-anchored decoy receptor that binds TRAIL with high affinity but lacks a cytoplasmic death domain, thereby competing with the death receptors DR4 and DR5 to inhibit TRAIL-mediated apoptosis at the cell surface (PMID:9314565, PMID:11350953). Its expression is transcriptionally controlled by p53, which binds a consensus element in the first intron to upregulate DcR1 after genotoxic stress, and by NF-κB, which acts through a proximal κB-site in a p50/Bcl3-dependent manner (PMID:14623878, PMID:25808868). In many cancers DcR1 is epigenetically silenced by CpG island promoter hypermethylation, sometimes in combination with hemizygous deletion, and demethylation restores its expression (PMID:11929838, PMID:19035483). Hepatitis B virus exploits HBx-mediated NF-κB activation of the DcR1 promoter to upregulate DcR1 in hepatocytes, thereby blunting TRAIL-dependent immune clearance and antiviral suppression of HBV replication (PMID:35226068).

1. 1997 High

   Identification of TRAIL-R3 as a GPI-anchored receptor that binds TRAIL but cannot signal apoptosis resolved how cells could engage TRAIL without dying, establishing the decoy receptor concept for TRAIL biology.

   Evidence Cloning, quantitative TRAIL-binding assays, structural analysis, and transient overexpression in cell lines

   PMID:9314565

   Open questions at the time

   • No endogenous loss-of-function data to confirm physiological decoy role
   • Mechanism by which GPI anchor prevents signaling not elucidated
2. 1999 High

   Demonstrating that DcR1 is a p53-inducible DNA damage-response gene explained how genotoxic stress could paradoxically protect certain cells from TRAIL-mediated killing.

   Evidence RT-PCR and reporter assays after ionizing radiation and MMS in cells with or without functional p53

   PMID:10435597

   Open questions at the time

   • Direct p53 binding site not yet mapped
   • Physiological relevance of p53-mediated DcR1 induction in vivo not tested
3. 2001 High

   Showing that NF-κB upregulates surface DcR1 and that its enzymatic removal restores TRAIL sensitivity established DcR1 as a dominant-negative TRAIL inhibitor operating at the plasma membrane.

   Evidence cRel overexpression, TNFα stimulation, PI-PLC cleavage of GPI-anchored DcR1, and TRAIL apoptosis assays

   PMID:11350953

   Open questions at the time

   • Specific NF-κB binding site in DcR1 promoter not mapped
   • Contribution of individual NF-κB subunits not determined
4. 2002 High

   Discovery that DcR1 promoter CpG island hypermethylation causes tumor-specific silencing revealed an epigenetic mechanism by which cancers lose a TRAIL decoy, with implications for TRAIL-based therapy sensitivity.

   Evidence Bisulfite sequencing in neuroblastoma and other tumor lines; 5-aza-2′-deoxycytidine restores expression

   PMID:11929838

   Open questions at the time

   • Whether methylation-mediated DcR1 loss sensitizes tumors to endogenous TRAIL in vivo not shown
   • Mechanism recruiting methyltransferases to DcR1 locus unknown
5. 2003 High

   Mapping of a p53-binding element in the first intron and delineation of the minimal TATA-box-containing promoter provided the direct cis-regulatory architecture for p53-dependent and p53-independent transcriptional control of DcR1.

   Evidence EMSA demonstrating p53 binding to intronic element; luciferase reporter assays with wild-type and mutant p53, E6-expressing cells, and promoter deletions

   PMID:12417331 PMID:14623878

   Open questions at the time

   • Chromatin context of p53 binding (ChIP) not shown
   • Identity of p53-independent transcriptional activators in doxorubicin-treated cells unknown
6. 2008 High

   Reciprocal knockdown and overexpression of DcR1 across p53-defined colon cancer lines demonstrated that p53-driven DcR1 induction functionally antagonizes oxaliplatin/TRAIL synergy, establishing DcR1 as a druggable resistance node in combination therapy.

   Evidence siRNA knockdown and forced expression of DcR1 in colon cancer lines with defined p53 status; apoptosis quantification

   PMID:18345033

   Open questions at the time

   • Whether DcR1 depletion improves combination therapy in vivo not tested
   • Stoichiometric relationship between DcR1 and DR4/DR5 on surface not quantified
7. 2009 High

   Identification of concurrent hemizygous deletion and promoter methylation in prostate cancer showed that biallelic inactivation of DcR1 occurs through complementary genetic and epigenetic hits.

   Evidence SNP array for copy-number analysis and bisulfite sequencing in clinical prostate cancer specimens; 5-aza-2′-deoxycytidine rescue in PC3 cells

   PMID:19035483

   Open questions at the time

   • Functional consequence of DcR1 loss for prostate cancer TRAIL sensitivity not tested directly
   • Whether deletion is selected for or bystander to neighboring loci unclear
8. 2015 High

   Defining the proximal κB-site and p50/Bcl3 dependence for temozolomide-induced DcR1 expression, together with in vivo xenograft validation, resolved the specific NF-κB subunit pathway and established DcR1 depletion as a strategy to enhance alkylating-agent therapy in glioma.

   Evidence κB-site mutagenesis in reporter, siRNA/overexpression of DcR1, intracranial xenograft survival studies

   PMID:25808868

   Open questions at the time

   • ChIP confirmation of endogenous p50/Bcl3 occupancy at κB-site not provided
   • Whether DcR1 inhibits Fas pathway by direct ligand competition or indirect mechanism not resolved
9. 2020 Medium

   Placing DcR1 downstream of HIF-1α as a negatively regulated target in traumatic brain injury added a hypoxia-responsive layer to DcR1 transcriptional control in neurons.

   Evidence HIF-1α inhibitor/agonist treatment in rat TBI model and HIF-1α siRNA in vitro; Western blot and immunofluorescence

   PMID:32848609

   Open questions at the time

   • Direct HIF-1α binding to DcR1 promoter not demonstrated
   • Mechanism of negative regulation (direct repression vs. indirect) unknown
   • Single-lab finding not yet independently replicated
10. 2023 High

    Demonstrating that HBV/HBx upregulates DcR1 via NF-κB to simultaneously block TRAIL-mediated apoptosis and TRAIL-dependent antiviral suppression revealed a viral immune evasion strategy centered on the decoy receptor.

    Evidence cDNA microarray/NGS in HBV-infected humanized mouse livers, luciferase promoter assays mapping -969 to -479 region, in vitro HBV replication models, antiviral rescue

    PMID:35226068

    Open questions at the time

    • Exact NF-κB binding element within the -969 to -479 region not fine-mapped
    • Whether other hepatotropic viruses exploit DcR1 similarly is untested

• The structural basis for TRAIL binding by GPI-anchored DcR1, the precise stoichiometry of DcR1/DR4/DR5 competition at the membrane, and whether DcR1 has signaling-independent functions beyond ligand sequestration remain unresolved.
• No crystal or cryo-EM structure of DcR1–TRAIL complex
• Quantitative surface competition model with DR4/DR5 lacking
• Potential non-apoptotic signaling through lipid-raft-associated DcR1 unexplored